174 related articles for article (PubMed ID: 29630643)
1. An antibody with Fab-constant domains exchanged for a pair of CH3 domains.
Wozniak-Knopp G; Stadlmayr G; Perthold JW; Stadlbauer K; Gotsmy M; Becker S; Rüker F
PLoS One; 2018; 13(4):e0195442. PubMed ID: 29630643
[TBL] [Abstract][Full Text] [Related]
2. Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors.
Goulet DR; Zwolak A; Williams JA; Chiu ML; Atkins WM
Proteins; 2020 May; 88(5):689-697. PubMed ID: 31702857
[TBL] [Abstract][Full Text] [Related]
3. Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells.
Jung ST; Reddy ST; Kang TH; Borrok MJ; Sandlie I; Tucker PW; Georgiou G
Proc Natl Acad Sci U S A; 2010 Jan; 107(2):604-9. PubMed ID: 20080725
[TBL] [Abstract][Full Text] [Related]
4. Engineered humanized dimeric forms of IgG are more effective antibodies.
Caron PC; Laird W; Co MS; Avdalovic NM; Queen C; Scheinberg DA
J Exp Med; 1992 Oct; 176(4):1191-5. PubMed ID: 1402660
[TBL] [Abstract][Full Text] [Related]
5. Structure-based stability engineering of the mouse IgG1 Fab fragment by modifying constant domains.
Teerinen T; Valjakka J; Rouvinen J; Takkinen K
J Mol Biol; 2006 Aug; 361(4):687-97. PubMed ID: 16876195
[TBL] [Abstract][Full Text] [Related]
6. Constant domain-exchanged Fab enables specific light chain pairing in heterodimeric bispecific SEED-antibodies.
Dietrich S; Gross AW; Becker S; Hock B; Stadlmayr G; Rüker F; Wozniak-Knopp G
Biochim Biophys Acta Proteins Proteom; 2020 Jan; 1868(1):140250. PubMed ID: 31295556
[TBL] [Abstract][Full Text] [Related]
7. Bispecific antibodies with Fab-arms featuring exchanged antigen-binding constant domains.
Benedetti F; Stracke F; Stadlmayr G; Stadlbauer K; Rüker F; Wozniak-Knopp G
Biochem Biophys Rep; 2021 Jul; 26():100959. PubMed ID: 33718630
[TBL] [Abstract][Full Text] [Related]
8. Differential inhibition of trastuzumab- and cetuximab-induced cytotoxicity of cancer cells by immunoglobulin G1 expressing different GM allotypes.
Namboodiri AM; Pandey JP
Clin Exp Immunol; 2011 Dec; 166(3):361-5. PubMed ID: 22059994
[TBL] [Abstract][Full Text] [Related]
9. Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays.
Lu Y; Vernes JM; Chiang N; Ou Q; Ding J; Adams C; Hong K; Truong BT; Ng D; Shen A; Nakamura G; Gong Q; Presta LG; Beresini M; Kelley B; Lowman H; Wong WL; Meng YG
J Immunol Methods; 2011 Feb; 365(1-2):132-41. PubMed ID: 21185301
[TBL] [Abstract][Full Text] [Related]
10. Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody.
Huang S; Li F; Liu H; Ye P; Fan X; Yuan X; Wu Z; Chen J; Jin C; Shen B; Feng J; Zhang B
MAbs; 2018; 10(6):864-875. PubMed ID: 30081724
[TBL] [Abstract][Full Text] [Related]
11. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format.
Shahied LS; Tang Y; Alpaugh RK; Somer R; Greenspon D; Weiner LM
J Biol Chem; 2004 Dec; 279(52):53907-14. PubMed ID: 15471859
[TBL] [Abstract][Full Text] [Related]
12. Engineered aglycosylated full-length IgG Fc variants exhibiting improved FcγRIIIa binding and tumor cell clearance.
Jo M; Kwon HS; Lee KH; Lee JC; Jung ST
MAbs; 2018; 10(2):278-289. PubMed ID: 29173039
[TBL] [Abstract][Full Text] [Related]
13. Generation and testing of engineered multimeric Fabs of trastuzumab.
Selis F; Sandomenico A; Cantile M; Sanna R; Calvanese L; Falcigno L; Dell'Omo P; Esperti A; De Falco S; Focà A; Caporale A; Iaccarino E; Truppo E; Scaramuzza S; Tonon G; Ruvo M
Int J Biol Macromol; 2020 Dec; 164():4516-4531. PubMed ID: 32941911
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies.
Muda M; Gross AW; Dawson JP; He C; Kurosawa E; Schweickhardt R; Dugas M; Soloviev M; Bernhardt A; Fischer D; Wesolowski JS; Kelton C; Neuteboom B; Hock B
Protein Eng Des Sel; 2011 May; 24(5):447-54. PubMed ID: 21498564
[TBL] [Abstract][Full Text] [Related]
15. Interaction between the antigen and antibody is controlled by the constant domains: normal mode dynamics of the HEL-HyHEL-10 complex.
Adachi M; Kurihara Y; Nojima H; Takeda-Shitaka M; Kamiya K; Umeyama H
Protein Sci; 2003 Oct; 12(10):2125-31. PubMed ID: 14500870
[TBL] [Abstract][Full Text] [Related]
16. In Vitro and In Vivo Comparison of Lymphocytes Transduced with a Human CD16 or with a Chimeric Antigen Receptor Reveals Potential Off-Target Interactions due to the IgG2 CH2-CH3 CAR-Spacer.
Clémenceau B; Valsesia-Wittmann S; Jallas AC; Vivien R; Rousseau R; Marabelle A; Caux C; Vié H
J Immunol Res; 2015; 2015():482089. PubMed ID: 26665156
[TBL] [Abstract][Full Text] [Related]
17. Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies.
Wu X; Sereno AJ; Huang F; Zhang K; Batt M; Fitchett JR; He D; Rick HL; Conner EM; Demarest SJ
MAbs; 2015; 7(2):364-76. PubMed ID: 25611120
[TBL] [Abstract][Full Text] [Related]
18. EFab domain substitution as a solution to the light-chain pairing problem of bispecific antibodies.
Cooke HA; Arndt J; Quan C; Shapiro RI; Wen D; Foley S; Vecchi MM; Preyer M
MAbs; 2018; 10(8):1248-1259. PubMed ID: 30215570
[TBL] [Abstract][Full Text] [Related]
19. Tribody [(HER2)
Oberg HH; Kellner C; Gonnermann D; Sebens S; Bauerschlag D; Gramatzki M; Kabelitz D; Peipp M; Wesch D
Front Immunol; 2018; 9():814. PubMed ID: 29725336
[TBL] [Abstract][Full Text] [Related]
20. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]